Research programme: targeted protein degradation therapeutics - C4 Therapeutics

Drug Profile

Research programme: targeted protein degradation therapeutics - C4 Therapeutics

Latest Information Update: 06 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator C4 Therapeutics
  • Developer Dana-Farber Cancer Institute
  • Class Small molecules
  • Mechanism of Action Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Mar 2017 C4 Therapeutics and Calico enter into a five year collaboration agreement to discover, develop and commercialise targeted protein degradation therapeutics for Cancer
  • 07 Jan 2016 C4 Therapeutics and Roche will develop TPD therapeutics for Cancer
  • 01 Jun 2015 Early research in Cancer in USA (unspecified route) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top